| |
| |
|
| Insider
Information: |
Bonney Michael W |
| Relationship: |
Director |
| City: |
Lexington |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
11 |
|
| Direct
Shares |
1,699,363 |
|
|
Indirect Shares
|
231,000 |
|
|
| Direct
Value |
$4,479,339 |
|
|
|
Indirect Value
|
$662,963 |
|
|
| Total
Shares |
1,930,363 |
|
|
| Total
Value |
$5,142,302 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
1
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-1.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -23.2%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
NPS Pharmaceuticals Inc |
NPSP |
Director |
2015-02-21 |
0 |
2005-05-17 |
0 |
Premium* |
|
|
H&Q Healthcare Investors |
HQH |
Director |
2014-06-24 |
1,860 |
2012-03-09 |
0 |
Premium* |
|
|
Tekla Life Sciences Investors |
HQL |
Director |
2014-06-24 |
2,388 |
2014-06-24 |
0 |
Premium* |
|
|
Tekla Healthcare Opportunities F... |
THQ |
Director |
2014-07-28 |
5,000 |
2014-07-28 |
0 |
Premium* |
|
|
Alnylam Pharmaceuticals Inc |
ALNY |
Director |
2023-12-27 |
16,029 |
2023-12-27 |
4,000 |
Premium* |
|
|
Tekla World Healthcare Fund |
THW |
Director |
2015-08-17 |
10,917 |
2015-08-17 |
0 |
Premium* |
|
|
Celgene Corp |
CELG |
|
2019-11-20 |
0 |
2019-11-20 |
0 |
Premium* |
|
|
Sarepta Therapeutics Inc |
SRPT |
Director |
2020-02-28 |
9,126 |
2018-03-05 |
0 |
Premium* |
|
|
Dianthus Therapeutics Ord Shs |
DNTH |
Director |
2018-06-25 |
215,346 |
2018-06-25 |
0 |
Premium* |
|
|
Kaleido Biosciences, Inc. |
KLDO |
Executive Chair, Direc... |
2019-03-04 |
1,426,196 |
2019-03-04 |
225,000 |
Premium* |
|
|
Bristol-Myers Squibb Co |
BMY |
Director |
2021-06-13 |
12,501 |
2021-06-13 |
2,000 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
42 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 2
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| NPSP |
NPS Pharmaceuticals Inc |
Director |
– • – |
2012-02-07 |
4 |
A |
$0.00 |
$0 |
D/D |
15,225 |
15,225 |
0 |
- |
|
| NPSP |
NPS Pharmaceuticals Inc |
Director |
– • – |
2013-02-07 |
4 |
A |
$0.00 |
$0 |
D/D |
15,225 |
19,225 |
0 |
- |
|
| SRPT |
Sarepta Therapeutics Inc |
Director |
– • – |
2018-03-05 |
4 |
A |
$0.00 |
$0 |
D/D |
3,418 |
3,418 |
0 |
- |
|
| DNTH |
Dianthus Therapeutics Ord... |
Director |
– • – |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
21,847 |
215,346 |
0 |
- |
|
| KLDO |
Kaleido Biosciences, Inc. |
Executive Chair |
• • – |
2019-03-04 |
4 |
A |
$0.00 |
$0 |
I/I |
225,000 |
225,000 |
0 |
- |
|
| KLDO |
Kaleido Biosciences, Inc. |
Executive Chair |
• • – |
2019-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
417,673 |
1,426,196 |
0 |
- |
|
| SRPT |
Sarepta Therapeutics Inc |
Director |
– • – |
2019-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
1,633 |
5,051 |
0 |
- |
|
| SRPT |
Sarepta Therapeutics Inc |
Director |
– • – |
2020-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
2,075 |
9,126 |
0 |
- |
|
| NPSP |
NPS Pharmaceuticals Inc |
Director |
– • – |
2013-02-07 |
4 |
AS |
$8.74 |
$46,541 |
D/D |
(5,325) |
13,900 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
Director |
– • – |
2023-12-27 |
4 |
AS |
$195.00 |
$5,850,000 |
D/D |
(30,000) |
16,029 |
0 |
% |
|
| NPSP |
NPS Pharmaceuticals Inc |
Director |
– • – |
2005-05-17 |
4 |
B |
$12.95 |
$51,800 |
D/D |
4,000 |
4,000 |
2.39 |
- |
|
| HQH |
H&Q Healthcare Investors |
Director |
– • – |
2012-03-09 |
4 |
B |
$15.80 |
$10,268 |
D/D |
650 |
650 |
2.39 |
- |
|
| THQ |
Tekla Healthcare Opportun... |
Director |
– • – |
2014-07-28 |
4 |
B |
$20.00 |
$100,000 |
D/D |
5,000 |
5,000 |
2.39 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
Director |
– • – |
2015-05-12 |
4 |
B |
$112.16 |
$224,320 |
I/I |
2,000 |
2,000 |
2.1 |
- |
|
| THW |
Tekla World Healthcare Fu... |
Director |
– • – |
2015-08-17 |
4 |
B |
$18.35 |
$200,294 |
D/D |
10,917 |
10,917 |
2.39 |
- |
|
| CELG |
Celgene Corp |
Director |
– • – |
2016-03-03 |
4 |
B |
$103.01 |
$206,028 |
I/I |
2,000 |
2,000 |
2.1 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
Director |
– • – |
2016-03-09 |
4 |
B |
$58.36 |
$116,720 |
I/I |
2,000 |
4,000 |
2.1 |
- |
|
| KLDO |
Kaleido Biosciences, Inc. |
Executive Chair |
• • – |
2019-02-28 |
4 |
B |
$13.95 |
$999,493 |
D/D |
71,520 |
1,008,523 |
2.81 |
- |
|
| SRPT |
Sarepta Therapeutics Inc |
Director |
– • – |
2019-09-09 |
4 |
B |
$86.74 |
$173,480 |
D/D |
2,000 |
7,051 |
2.39 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
Director |
– • – |
2019-12-04 |
4 |
B |
$58.90 |
$5,183 |
D/D |
88 |
7,189 |
2.39 |
- |
|
| NPSP |
NPS Pharmaceuticals Inc |
Director |
– • – |
2015-02-21 |
4 |
D |
$46.00 |
$639,400 |
D/D |
(13,900) |
0 |
0 |
- |
|
| CELG |
Celgene Corp |
|
– • – |
2019-11-20 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,209) |
0 |
0 |
- |
|
| CELG |
Celgene Corp |
|
– • – |
2019-11-20 |
4 |
D |
$0.00 |
$0 |
I/I |
(2,000) |
0 |
0 |
- |
|
| KLDO |
Kaleido Biosciences, Inc. |
Executive ChairOfficer |
• • – |
2019-02-27 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
937,003 |
|
- |
|
| BMY |
Bristol-Myers Squibb Co |
Director |
– • – |
2019-11-20 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
7,189 |
|
- |
|
42 Records found
|
|
Page 1 of 2 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
